Compass Therapeutics, Inc. (CMPX)

USD 1.42

(-7.19%)

Market Cap (In USD)

195.37 Million

Revenue (In USD)

-

Net Income (In USD)

-42.49 Million

Avg. Volume

449.52 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.765-2.34
PE
-
EPS
-
Beta Value
0.746
ISIN
US20454B1044
CUSIP
20454B104
CIK
1738021
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Thomas J. Schuetz M.D., Ph.D.
Employee Count
-
Website
https://www.compasstherapeutics.com
Ipo Date
2021-04-05
Details
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.